NASDAQ:ITCI

Intra-Cellular Therapies Stock Forecast, Price & News

$31.22

-1.13 (-3.49 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$30.96

Now: $31.22▼

$32.63

50-Day Range

$30.80

MA: $33.84▼

$36.98

52-Week Range

$16.00

Now: $31.22▼

$40.01

Volume428,522 shs

Average Volume601,605 shs

Market Capitalization$2.53 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.5

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ITCI

Previous Symbol

CUSIPN/A

CIK1567514

Webwww.intracellulartherapies.com

Phone646-440-9333

Employees383

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio19.59

Quick Ratio19.51

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$60,000.00

Price / Sales42,103.81

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.52 per share

Price / Book8.87

Profitability

EPS (Most Recent Fiscal Year)($2.68)

Net Income$-147,720,000.00

Net Margins-1,985.32%

Return on Equity-48.27%

Return on Assets-42.56%

Miscellaneous

Outstanding Shares80,917,000

Market Cap$2.53 billion

Next Earnings Date5/6/2021 (Estimated)

OptionableOptionable

Headlines

Intra-Cellular Therapies (NASDAQ:ITCI) Trading 4.7% Higher
April 15, 2021 | americanbankingnews.com

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected to Announce Earnings of -$0.80 Per Share
April 7, 2021 | americanbankingnews.com

Intra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up to $31.30
April 7, 2021 | americanbankingnews.com

Earnings Update: Here's Why Analysts Just Lifted Their Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Price Target To US$49.89
March 1, 2021 | nasdaq.com

Intra-Cellular Therapies, Inc.'s (ITCI) CEO Sharon Mates on Q4 2020 Results - Earnings Call Transcript
February 27, 2021 | seekingalpha.com

Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Transcript
February 26, 2021 | finance.yahoo.com

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
February 25, 2021 | msn.com

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
February 25, 2021 | finance.yahoo.com

Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes
February 24, 2021 | finance.yahoo.com

Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
February 24, 2021 | finance.yahoo.com

First Week of April 16th Options Trading For Intra-Cellular Therapies (ITCI)
February 22, 2021 | nasdaq.com

Intra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings
February 22, 2021 | feeds.benzinga.com

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
February 22, 2021 | finance.yahoo.com

Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 19, 2021 | benzinga.com

Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 19, 2021 | finance.yahoo.com

Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast
February 17, 2021 | finance.yahoo.com

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
February 10, 2021 | finance.yahoo.com

CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
January 21, 2021 | finance.yahoo.com

First Week of ITCI March 19th Options Trading
January 15, 2021 | nasdaq.com

Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.68 out of 5 stars

Medical Sector

298th out of 2,024 stocks

Pharmaceutical Preparations Industry

131st out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.43, Intra-Cellular Therapies has a forecasted upside of 51.9% from its current price of $31.22.
Amount of Analyst Coverage
Intra-Cellular Therapies has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
Intra-Cellular Therapies has received 447 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Intra-Cellular Therapies has received 420 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Intra-Cellular Therapies has received 51.56% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote “Outperform” if you believe ITCI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,812,703.00 in company stock.
Percentage Held by Insiders
Only 18.20% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
79.10% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($3.32) to ($3.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -9.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -9.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 8.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$31.22

-1.13 (-3.49 %)

(As of 04/16/2021 04:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

Is Intra-Cellular Therapies a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies or view top-rated stocks.

What stocks does MarketBeat like better than Intra-Cellular Therapies?

Wall Street analysts have given Intra-Cellular Therapies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intra-Cellular Therapies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Intra-Cellular Therapies.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Wednesday, February, 24th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.09. The biopharmaceutical company had revenue of $12.45 million for the quarter, compared to analyst estimates of $12.45 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 48.27% and a negative net margin of 1,985.32%.
View Intra-Cellular Therapies' earnings history.

How has Intra-Cellular Therapies' stock been impacted by COVID-19 (Coronavirus)?

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ITCI stock has increased by 75.7% and is now trading at $31.22.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ITCI?

7 brokers have issued 12-month target prices for Intra-Cellular Therapies' shares. Their forecasts range from $36.00 to $70.00. On average, they expect Intra-Cellular Therapies' share price to reach $47.43 in the next twelve months. This suggests a possible upside of 51.9% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies or view top-rated stocks among Wall Street analysts.

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:

Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 68, Pay $1.52M)
Mr. Lawrence J. Hineline CPA, CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec. (Age 65, Pay $693.55k)
Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel & Sec. (Age 48, Pay $837.47k)
Mr. Mark Neumann, EVP & Chief Commercial Officer (Age 58, Pay $914.35k)
Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 70)
Mr. Juan Fernando Sanchez, VP of Corp. Communications & Investor Relations (Age 50)
Ms. Karen Patruno Sheehy Esq., Sr. VP & Chief Compliance Officer (Age 59)
Dr. Suresh K. Durgam M.D., Sr. VP & Chief Medical Officer
Dr. Michael Olchaskey, Sr. VP & Head of Regulatory Affairs
Mr. John A. Bardi, Sr. VP of Market Access, Policy & Gov. Affairs

Who are some of Intra-Cellular Therapies' key competitors?

Some companies that are related to Intra-Cellular Therapies include Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Evotec (EVTCY), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Perrigo (PRGO) and Allakos (ALLK).
View all of ITCI's competitors.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a number of retail and institutional investors. Top institutional investors include First Midwest Bank Trust Division (0.11%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies.

Which institutional investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies or view top insider-selling stocks.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $31.22.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies has a market capitalization of $2.53 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

Intra-Cellular Therapies employs 383 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

Where are Intra-Cellular Therapies' headquarters?

Intra-Cellular Therapies is headquartered at 430 EAST 29TH STREET, NEW YORK NY, 10016.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]

This page was last updated on 4/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here